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Abstract
Background: Lafora disease (LD, OMIM 254780) is a fatal neurodegenerative disorder produced mainly by mutations
in two genes: EPM2A, encoding the dual specificity phosphatase laforin, and EPM2B, encoding the E3-ubiquitin ligase
malin. Although it is known that laforin and malin may form a functional complex, the underlying molecular
mechanisms of this pathology are still far from being understood.
Methods: In order to gain information about the substrates of the laforin/malin complex, we have carried out a yeast
substrate-trapping screening, originally designed to identify substrates of protein tyrosine phosphatases.
Results: Our results identify the two muscular isoforms of pyruvate kinase (PKM1 and PKM2) as novel interaction
partners of laforin.
Conclusions: We present evidence indicating that the laforin/malin complex is able to interact with and ubiquitinate
both PKM1 and PKM2. This post-translational modification, although it does not affect the catalytic activity of PKM1, it
impairs the nuclear localization of PKM2.
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Background
Lafora disease (LD, OMIM 254780) is a rare fatal type of
progressive myoclonus epilepsy that initially manifests
during adolescence. Recessive mutations in two main loci,
EPM2A or EPM2B, are known to produce LD ([1–3]).
The EPM2A gene encodes the dual-specificity phosphat-
ase laforin and the EPM2B gene encodes the E3-ubiquitin
ligase malin. Although it is known that both proteins form
a functional complex ([4–6]), the underlying molecular
mechanisms of this pathology are still far from being
understood. For this reason the search for substrates of
the laforin/malin complex has been a good strategy to
understand the molecular basis of this pathology. Differ-
ent techniques have been used with this aim, from regular
yeast two-hybrid screening, using either laforin or malin
as bait, to co-immunoprecipitation/pull down analyses
and functional interactions. All these approaches have
identified several putative substrates of the laforin/malin
complex that have enriched our knowledge on the
different cellular pathways where laforin and malin may
participate (see [7] for a review).
In order to identify novel phospho-protein substrates
of laforin, we have used the yeast substrate-trapping
system described by Fukada and Noda [8], designed to
identify substrates of protein tyrosine phosphatases. This
technique is based on the use of phosphatase mutants
which harbor a substitution in invariant amino acid resi-
dues in the catalytic domain, making them catalytically
inactive, but retaining the capability to recognize the
phosphorylated substrate. In addition, the yeast model
co-expresses a wide spectrum tyrosine kinase (i.e., v-src),
which will phosphorylate putative target substrates. In
this way, the possibilities to identify putative phospho-
tyrosine containing substrates of a particular phosphatase
are enhanced. Here, we have identified the two muscular
isoforms of pyruvate kinase (PKM1 and PKM2) as novel
interaction partners of laforin. Pyruvate kinase regulates
the rate-limiting final step of glycolysis, which catalyzes
the transfer of a high-energy phosphate group from phos-
phoenolpyruvate (PEP) to adenine diphosphate (ADP),
yielding one molecule of pyruvate and one molecule of
adenosine triphosphate (ATP) (see [9] for review). Four
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isoforms of pyruvate kinase have been described in mam-
mals: PKR, present mainly in erythrocytes; PKL, present
in liver, kidney, small intestine and pancreas; PKM1,
present in muscle, heart and brain; and PKM2, widely dis-
tributed and also present in fetal tissues and cancer cells
([9, 10]). PKM1 and PKM2 result from an alternative spli-
cing of two mutually exclusive exons of the PKM gene
(exon 9 is present in PKM1 whereas exon 10 is present in
PKM2). This difference in exon usage results in proteins
that differ only in 22 amino acids distributed along a small
region of 56 amino acids [from residue 378 to 434 [11],
(Fig. 1a, black box)]. These changes confer distinct kin-
etic and regulatory properties to PKM1 and PKM2:
although both PKM1 and PKM2 are proteins of 531 aa,
with a similar molecular weight (58 kDa) and similar
structural domains ([9, 10]) (Fig. 1a), only PKM1 is fully
active whereas PKM2 may form inactive dimeric com-
plexes ([9, 10]).
In this work we present evidence of the interaction
between laforin and both PKM1 and PKM2. As a result
of this interaction, we show that the laforin/malin com-
plex ubiquitinates PKM1 and PKM2 and that this post-
translational modification, although it does not affect
the catalytic activity of PKM1, it impairs the nuclear
localization of PKM2.
Results
The muscular isoform of Pyruvate Kinase (PKM) interacts
with laforin
As indicated at the Background section, in this work we
have used the yeast substrate-trapping system [8], designed
to identify substrates of protein tyrosine phosphatases, to
Fig. 1 PKM1 and PKM2 interact with laforin. a Yeast substrate-trapping system with LexA-laforin C266S was used to identify putative partners from
a human brain library. Five clones corresponding to different lengths of PKM1 and PKM2 were selected (in brackets the amino acids included in
the clones corresponding either to PKM1 of PKM2). A diagram of the different domains in PKMs is presented (black bar indicates the region that
is different between PKM1 and PKM2). The strength of the interaction of these clones with either LexA-laforin C266S or LexA-laforin wild type was
measured (β-galactosidase activity). b Co-immunoprecipitation analysis of PKM1 and PKM2 with laforin. HEK293 cells were transfected with the
indicated plasmids. Crude extracts and co-immunoprecipitation analyses with anti-FLAG antibody was performed as indicated in Methods.
Proteins in the immunoprecipitates and in the crude extracts (CE, 25 μg) were analyzed by western blotting using the indicated antibodies
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screen for possible phospho-protein substrates of laforin.
Following the conditions required for this type of screening,
we initially constructed a catalytically inactive laforin mu-
tant, Laf-C266S, which affects the key Cys residue in the
catalytic site [7]. This mutant retained the capability to
recognize laforin binding partners (i.e. malin, R5/PTG)
(not shown). A yeast strain co-expressing LexA-Laforin
C266S and the protein tyrosine kinase v-src was trans-
formed with a human brain cDNA library, and after
screening more than 300,000 independent transfor-
mants, we recovered 97 putative positive clones. Unfor-
tunately, 58 of them were false positives since when we
purified the corresponding plasmids they were not able to
reproduce the two-hybrid interaction. Among the other
39 positive clones, we identified already known laforin
binding partners, such as laforin itself and R5/PTG, what
validated the technique (Table 1). The rest of the clones
interacted with laforin with different strength (in Table 1
we describe only the 17 clones that presented the stron-
gest interaction). Among them, we focused our attention
to those that coded for the two muscular isoforms of
pyruvate kinase (PKM1 and PKM2), as we recovered five
PKM-related clones which encoded for different frag-
ments of both PKM1 and PKM2 (Fig. 1a). In these clones
the interaction with laforin was much stronger when only
the C-terminal part of PKMs was present in the clones
[clones p21 and p89 (aa 383–531 of PKM2) and p52 (aa
366–531 of PKM1)], and decreased when larger parts of
the protein were present in the clones [clone p58 (aa 274–
531 of PKM1), clone p36 (aa 143–531 of PKM2)] (Fig. 1a).
We repeated the two-hybrid interaction of these clones
using LexA-Laforin WT as bait and found that the inter-
action was maintained although at lower intensity (Fig. 1a).
We also noticed that all these interactions were main-
tained under growth conditions that prevented the expres-
sion of v-src, indicating that, contrary to the experimental
design, they were not dependent on the phosphorylation
of the substrate by this protein kinase.
In order to confirm the interaction between laforin
and the PKM1 and PKM2 isoforms, we carried out a co-
immunoprecipitation analysis in mammalian cells. First,
we obtained by PCR the full length cDNAs of PKM1
and PKM2 from the human brain cDNA library and
subcloned them into plasmid pCMV-myc, to allow their
expression in mammalian HEK293 cells. We observed
that the expression of the PKM1 isoform yielded a protein
with a slightly faster mobility in SDS-PAGE, probably due
to differences in protein sequence in comparison to
PKM2 (Fig. 1b. third panel). We co-expressed in HEK293
cells the PKM1 and PKM2 isoforms and laforin (tagged
with a FLAG epitope) either wild type or C266S, immuno-
precipitated the crude extracts with anti-FLAG antibody
and analyzed the immunoprecipitates by western blotting
using anti-FLAG and anti-myc antibodies. As shown in
Fig. 1b (top panel) both laforin-WT and laforin-C266S
were able to co-immunoprecipitate both myc-PKM1 and
myc-PKM2 isoforms. Taken together, these results indi-
cate that laforin interacts with both PKM1 and PKM2,
and that the phosphatase activity of laforin is dispensable
for the interaction with the PKMs isoforms. We tried to
repeat the co-immunoprecipitation experiment with en-
dogenous levels of proteins but unfortunately we did not
find any reliable commercial antibody which recognized
endogenous levels of laforin.
The laforin/malin complex polyubiquitinates PKM
isoforms, attaching K63-linked ubiquitins
It is known that laforin forms a functional complex with
the E3-ubiquitin ligase malin, in which laforin recognizes
the substrates that are eventually ubiquitinated by malin.
In order to check if the interaction between PKM1 and
PKM2 and laforin resulted in the ubiquitination of the
PKM isoforms, we co-expressed in HEK293 cells myc-
PKM1 or myc-PKM2, laforin, malin and a 6xHis-tagged
ubiquitin. The 6xHis tag present in the ubiquitin allows
the recovery of polyubiquitinated forms by metal affinity
Table 1 Positive clones identified in substrate-trap screening of a human brain cDNA library using LexA-laforin C266S as bait. Yeast
THY-AP4 cells transformed with plasmid pBridge-laforin C266S were co-transformed with a human brain cDNA library in pACT2
No. of positive clones Encoded protein Uniprot number Intensity of interaction
5 Pyruvate kinase PKM1/PKM2 Q504U3 From ++ to +++
3 E3 ubiquitin ligase TOPORS Q9NS56 ++
3 Cytochrome C oxidase subunit 5A P20674 ++
1 Laforin (EPM2A) O95278 +++
1 PP1 regulatory subunit R5/PTG (PPP1R3C) Q9UQK1 ++
1 G/T mismatch-specific thymine DNA glycosylase Q13569 +++
1 26S proteasome regulatory subunit 6A P17980 ++
1 HMG domain-containing protein 4 Q9UGU5 ++
1 Translation initiation factor eIF-2B subunit alpha Q14232 ++
Positive clones were confirmed, subjected to BLAST analysis and protein interaction estimated by β-galactosidase filter lift assays (+++, when the blue color
appeared in less than 5 min; ++, when the blue color appeared between 5 and 20 min)
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chromatography in the presence of guanidinium hydro-
chloride, an inhibitor of the action of deubiquitinases
[12]. As shown in Fig. 2a, the laforin/malin complex was
able to promote the polyubiquitination of PKM2 (lane 4).
This modification was dependent on the presence of the
laforin/malin complex, since it was drastically reduced in
its absence (lane 1) or when only laforin or malin were
expressed in the cells (lanes 2 and 3 respectively). Similar
results were obtained when PKM1 was assayed in the
same way (not shown). This ubiquitination was specific of
the laforin/malin complex since we did not observe this
modification when we co-expressed Mdm2, an unrelated
E3-ubiquitin ligase [lane 6 in Fig. 2a for PKM2; similar
results were obtained for PKM1 (not shown)].
In order to analyze the topology of the laforin/malin-in-
duced polyubiquitinated chains in PKMs, we co-expressed
in HEK293 cells mutated forms of ubiquitin that pre-
vented the formation of ubiquitin chains in either K48
(K48R mutant) or K63 (K63R mutant) (K48-linked polyu-
biquitin chains signal proteins to be degraded by the pro-
teasome, whereas K63-linked polyubiquitin chains play a
role in cell signaling and other physiological processes).
As shown in Fig. 2b, in the presence of K48R-ubiquitin, a
similar pattern of polyubiquitination of PKM1 and PKM2
by the laforin/malin complex was obtained (lanes 3 and 7,
respectively), whereas in the presence of K63R-ubiquitin,
no polyubiquitinated forms were obtained (lanes 4 and 8,
respectively). These results indicate that the laforin/malin
complex promotes the polyubiquitination of PKM1 and
PKM2 through the attachment of K63-linked ubiquitin
moieties. This topology was similar to the one found in
other substrates of the laforin/malin complex, such as R5/
PTG and AMPK subunits [13], and suggests that the
modified PKMs may be involved in cellular functions not
related to proteasomal degradation.
Consequences of the action of the laforin/malin complex
on the biochemical properties of PKM1 and PKM2
We analyzed next the effect of the laforin/malin complex
on the enzymatic activity of PKMs. With this aim, the
pyruvate kinase activity present in HEK293 cells express-
ing PKM1 or PKM2 and co-expressing or not the laforin/
malin complex was measured by standard methods. As
expected, the overexpression of PKM1 increased the pyru-
vate kinase activity over endogenous levels (expressed as
Units/mg total protein in the extract) (Fig. 3a, white bars).
The activity in the extract was increased further if the cells
co-expressed the laforin/malin complex (Fig. 3a, black
bars) but the co-expression of laforin alone (Fig. 3a, grey
bars) did not have this effect. On the contrary, the overex-
pression of PKM2 did not enhance the pyruvate kinase
activity over endogenous levels (Fig. 3a) (what was in
agreement with the reported reduced activity of this iso-
form [10]), and the laforin/malin complex had no effect
on its activity (Fig. 3a). Although at first glance these re-
sults could suggest that the laforin/malin complex in-
creased the intrinsic enzymatic activity of PKM1, we think
that this is a misleading conclusion, since the steady-state
levels of PKM1 were higher in cells expressing the laforin/
malin complex (Fig. 3b, compare lane 4 with lane 6). So,
we think that the increase in the total pyruvate kinase
activity detected in cells co-expressing PKM1 and the
laforin/malin complex is just a reflection of more amount
of the PKM1 protein being present in the extracts. We
also observed that the laforin/malin complex did not
Fig. 2 The laforin/malin complex polyubiquitinates PKM isoforms
attaching K63-linked ubiquitins. a and b HEK293 cells expressing
the indicated plasmids were analyzed for in vivo ubiquitination as
indicated in Methods. Proteins bound to the metal affinity column
(Bound) and those present in the crude extracts (CE, 25 μg) were
analyzed by western blotting using the indicated antibodies. The
position of polyubiquitinated proteins is indicated. The fuzzy bands
in the CE are probably due to the presence of 6 M guanidinium
hydrochoride in the extracts
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modify the total endogenous enzymatic activity of PKM
isoforms present in Hek293 cells (transformed with an
empty vector; Fig. 3a, empty).
We repeated the assay with cells expressing the catalyt-
ically inactive laforin C266S form. As shown in Fig. 3c, the
laforin C266S/malin complex was also able to increase the
total enzymatic activity and the steady-state levels of
PKM1 in the cells, indicating that this effect was not
dependent on the phosphatase activity of laforin.
Altered subcellular location of PKM2 due to the laforin/
malin complex
It has been described that both PKM1 and PKM2 are
cytosolic proteins, what is consistent with their role in
the glycolytic pathway ([14, 15]). However, PKM2 but
not PKM1 is also able to translocate to the nucleus,
where it acts as a protein kinase and regulates gene
expression in different ways ([16–18]). In order to check
whether the ubiquitination of PKM2 by the laforin/malin
complex could affect its translocation to the nucleus, we
transfected human osteosarcoma U2OS cells [which are
larger than HEK293 cells, so the different subcellular
compartments (especially nucleus) are better observed]
with myc-PKM2 in the presence or absence of FLAG-
laforin and HA-malin. Transfected cells were treated or
not with UV light (120 mJ/cm2; 120 s) to induce the
accumulation of PKM2 into the nucleus [19]. Cells were
then analyzed by immunofluorescence using anti-PKM2
and anti-HA (to detect the localization of malin, a pro-
tein enriched in the nucleus) antibodies. In agreement
with previous reports [19], treatment with UV light of
the cells containing myc-PKM2 and transformed with an
empty HA-vector promoted the nuclear accumulation of
PKM2 (Fig. 4a); 60 % of the cells presented a nuclear ac-
cumulation of PKM2 after UV-treatment in contrast to
30 % in the untreated sample (Fig. 4c). However, the
expression of the laforin/malin complex produced a re-
duction in the number of cells containing PKM2 at the
nucleus in both UV treated and untreated cells [Fig. 4b;
compare cells expressing malin (white arrows) with
other cells that do not express malin]: in untreated cells,
only 18 % of cells expressing the laforin/malin complex
displayed a nuclear accumulation of PKM2, in contrast
to 30 % in cells containing an empty plasmid, and in
UV-treated cells, only 47 % of cells expressing the
laforin/malin complex had a nuclear PKM2, in contrast
to 60 % in cells containing an empty plasmid (Fig. 4c).
Taken all these results together, we suggest that the
laforin/malin dependent ubiquitination of PKM2 par-
tially impairs its nuclear localization.
Discussion
In this work we describe additional substrates of the
laforin/malin complex, namely the muscular isoforms of
pyruvate kinase (PKM1 and PKM2). We present evidence
of the interaction between laforin and both PKM1 and
PKM2, and as a result of this interaction, we show that
the laforin/malin complex ubiquitinates both PKM1 and
PKM2 by attaching K63-linked polyubiquitin chains.
Fig. 3 Effect of the laforin/malin complex on the enzymatic activity of
the PKM isoforms. a Crude extracts from HEK293 cells expressing the
indicated plasmids were used to determine the pyruvate kinase
enzymatic activity as indicated in Methods. The results were plotted as
Units/mg total protein in the extracts (data are the mean of at least
three independent experiments; bars indicate standard deviation;
**p < 0.01). b Crude extracts from panel a were also analyzed by
SDS-PAGE and immunoblotting using the indicated antibodies.
c HEK293 cells expressing myc-PKM1 were transfected with the
indicated plasmid. Crude extracts were obtained and the pyruvate
kinase enzymatic activity measured as in panel a) (data are the
mean of at least three independent experiments; bars indicate
standard deviation; **p < 0.01). Crude extracts were also analyzed
by SDS-PAGE and immunoblotting using the indicated antibodies
(right panel)
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Fig. 4 The laforin/malin complex alters the subcellular localization of PKM2. a U2OS cells were transfected with plasmid pCMV-myc-PKM2. Cells
were then treated or not with UV light (120 mJ/cm2; 120 s) to induce the accumulation of PKM2 into the nucleus. The localization of PKM2 was
determined by immunofluorescence using anti-PKM2 antibodies (see Methods). DAPI staining was also performed to define the position of the
nuclei. A merge image is presented. Scale bars are indicated. b U2OS cells expressing plasmid pCMV-myc-PKM2 were co-transfected with plasmids
pFLAG-laforin and pCMV-HA-malin. Then, cells were treated of not with UV light as above. Panel shows the result in UV-treated cells. The localization
of malin, a nuclear protein, and PKM2 was determined by immunofluorescence using anti-HA and anti-PKM2 antibodies, respectively. c The percentage
of cells having a nuclear localization of PKM2 was determined in 100 cells from all the conditions. PKM-N: cells that present PKM2 inside the nucleus;
PKM-C: cells that present PKM2 outside of the nucleus
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These results are in agreement with recent data from the
GGBase indicating that PKM2 was ubiquitinated at differ-
ent sites (https://gygi.med.harvard.edu/ggbase/) and indi-
cate for the first time that in the ubiquitination reaction
participates, at least, the laforin/malin E3-ubiquitin ligase
complex. Therefore, ubiquitination of PKMs should be
added to the list of post-translational modifications that
suffer these proteins [14]. The laforin/malin dependent
ubiquitination of PKM1 and PKM2 did not modify their
corresponding catalytic activities. However, we noticed
that this post-translational modification increased the
steady-state levels of the proteins, probably because the
modified forms were more resistant to their proteolytic
turnover. In this way, the effect of the laforin/malin
dependent modification of PKM1 and PKM2 resembles
that of AMPKβ subunits (other substrates of the laforin/
malin complex) since also higher steady-state levels of
these subunits were observed upon the action of the
laforin/malin complex [13]. It is worth to point out that
stabilization of PKM1 and PKM2 levels also occurs when
a phosphatase inactive form of laforin (laforin C266S) is
expressed, indicating that the phosphatase activity of
laforin may not be required for inducing the malin-
mediated polyubiquitination of PKM1 and PKM2, as
already demonstrated in other laforin/malin substrates,
such as R5/PTG or R6, two regulatory subunits of protein
phosphatase type1 ([6, 20]).
We next studied the effect of the laforin/malin
dependent polyubiquitination on the subcellular distri-
bution of PKMs. It has been described that PKM2 but
not PKM1 is able to translocate to the nucleus, where it
displays specific functions ([14, 15]). This is probably
due to the presence of a nuclear localization signal
(NLS) in the specific region (aa 378 to 434) of PKM2,
not present in PKM1. This NLS allows PKM2 to interact
with members of the importin family, who mediate in
the translocation of PKM2 to the nucleus [16]. Recently,
it was reported that PKM2 interacted with the E3-
SUMO ligase PIAS3 and this resulted in the sumoyla-
tion of PKM2 and in an enhancement of its nuclear
localization [21]. On the contrary, our results suggest
that the laforin/malin dependent ubiquitination of
PKM2 interferes with the localization of PKM2 to the
nucleus. Perhaps ubiquitination of PKM2 affects its rec-
ognition by the importin machinery, resulting in an im-
pairment of nuclear translocation. Alternatively,
ubiquitination of PKM2 could interfere with its sumoyla-
tion since both processes affect similar Lys residues and,
in some cases, the introduction of one modification (i.e.
ubiquitination) prevents the alternative post-translational
alteration by the other (sumoylation) ([22, 23]). This nega-
tive relationship between ubiquitination and sumoylation
might affect nuclear translocation of PKM2, as it has
already been documented in other cases [24].
Conclusions
We present evidence indicating that the laforin/malin
complex is able to interact with and ubiquitinate both
muscular isoforms of pyruvate kinase (PKM1 and
PKM2). This post-translational modification, although it
does not affect the catalytic activity of PKM1, it impairs
the nuclear localization of PKM2.
Methods
Microorganisms, culture conditions and genetic methods
Escherichia coli DH5α strain was used as the host strain
for plasmid constructions and protein production. It was
grown in LB (1 % peptone, 0.5 % yeast extract, 1 % NaCl,
pH 7.5) medium supplemented with 50 mg/l ampicillin.
Yeast strain used in this work was THY-AP4 (MATa,
ura3, leu2, lexA::lacZ::trp1, lexA::HIS3, lexA::ADE2).
Yeast transformation was carried out using the lithium
acetate protocol [25]. Yeast cultures were grown in syn-
thetic complete (SC) medium lacking the corresponding
supplements to maintain selection for plasmids [26].
Plasmids
pCMV-HA-laforin, pFLAG-laforin, pFLAG-laforin C266S
and pcDNA3-HA-malin plasmids were described previ-
ously [6]. Plasmids pBridge-laforin and pBridge-laforin
C266S were obtained by subcloningBamHI/SalI fragments
containing either laforin WT or C266S in pBridgeLexA/v-
src [8]. Plasmids pCMV-myc-PKM1 and pCMV-myc-
PKM2 were obtained by subcloning an EcoRI/XhoI frag-
ment containing the corresponding ORF in pCMV-myc
vector. Other plasmids used in this study were pCMV-
6xHisUbiq (from Dr. M. Rodriguez, Proteomics Unit, CIC-
BioGUNE, Vizcaya, Spain); pCMV-6xHisUbiq-K48R and
pCMV-6xHisUbiq-K63R (from Dr. Ch. Blattner, Institute of
Toxicology and Genetics, Karlsruhe Institute of Technol-
ogy, Karlsruhe, Germany); pCMV-Mdm2 (from Dr. M.
Gentry, University of Kentucky, Lexington, KY; [27]).
Two-hybrid screening and analysis
A modified form of yeast two-hybrid screening named
yeast substrate-trapping system [8] was used to iden-
tify proteins that interacted with LexA-laforin C266S
(plasmid pBridge-laforin C266S). Plasmid pBridge-
laforin C266S also contains the ORF corresponding to the
mammalian protein kinase v-src under the control of the
MET25 promoter. Saccharomyces cerevisiae THY-AP4
strain containing pBridge-laforin C266S plasmid was
transformed with a commercial human brain cDNA
library in pACT2 vector (Clontech, Madrid, Spain). Trans-
formants were selected in SC + 2 % glucose plates lacking
tryptophan, leucine, methionine and histidine and were
subsequently screened for β-galactosidase activity using a
filter lift assay [28]. pACT2-plasmids were recovered
from positive clones and used to transform again S.
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cerevisiae THY-AP4 strain containing pBridge-laforin
C266S or laforin WT, to confirm the interaction. The
strength of the interaction was determined by measur-
ing β-galactosidase activity in permeabilized yeast cells
and expressed in Miller units as described by Ludin
and collaborators [29].
Cell culture, transfection and preparation of crude
extracts
Human embryonic kidney (HEK293) and human osteosar-
coma (U2OS) cells were grown in Dulbecco’s modified
Eagle’s medium (Lonza, Barcelona, Spain), supplemented
with 100 units/ml penicillin, 100 μg/ml streptomycin,
2 mM glutamine and 10 % of inactivated fetal bovine
serum (Lonza, Barcelona, Spain) in a humidified atmos-
phere at 37 °C with 5 % CO2. When indicated, cells were
transfected with 1 μg of each plasmid using X-treme
GENE HP transfection reagent (Roche Diagnostics,
Barcelona, Spain) according to the manufacturer’s in-
structions. Cell extracts were prepared using lysis buffer A
[25 mMTrisHCl at pH 7.4, 15 mM EDTA at pH 8, 50
mMNaF, 0.6 M sucrose, 15 mM Na4P2O7, 1 % nonidet
P40, 10 mMNaCl, 1 mM PMSF, and a complete protease
inhibitor mixture (Roche Diagnostics, Barcelona, Spain)].
Cells were lysed by repeated passage through 24G × 5/8″
needle and whole lysates were centrifuged at 10,000 × g
for 15 min. The supernatants were collected and 25 μg of
total protein subjected to SDS-PAGE, transferred into
PVDF membrane and revealed with the appropriated
antibodies.
Co-immunoprecipitation and western blotting
Mammalian HEK293 cells were transfected with the
corresponding plasmids. Twenty-four hours after
transfection, cells were harvested with lysis buffer B
[50 mMTrisHCl pH 7.5, 10 mMNaCl, 2 mM EDTA,
15 % glycerol, 1 % nonidet P40, complete protease in-
hibitor cocktail (Roche Diagnostics, Barcelona, Spain)
and 1 mM PMSF]. Cells were lysed by repeated passage
through 24G×5/8″ needle, whole lysates were centrifuged
at 10,000 × g for 15 min and the soluble fraction was col-
lected for immunoprecipitation. Co-immunoprecipitation
experiments were carried out with 500 μg of soluble
protein extracts, in a final volume of 500 μl of lysis buffer,
adding 1 μl of anti-FLAG monoclonal antibodies (Sigma,
Madrid, Spain) as in [30]. For western blot analysis,
proteins (25 μg) were denatured using sample buffer (125
mMTrisHCl pH 6.8, 20 % Glicerol, 0.01 % bromophenol
blue, 4 % SDS) and heating to95 °C for 5 min. The sam-
ples were subjected to SDS-PAGE and transferred onto
PVDF membranes (Millipore, Madrid, Spain). Membranes
were blocked with 5 % milk in TBS-tween for 1 h and
incubated with the following specific antibodies: anti-myc,
anti-FLAG, anti-HA and anti-actin from Sigma (Madrid,
Spain); anti-Mdm2 from Santa Cruz Biotechnology
(Madrid, Spain). Thereafter, blots were washed with
TBS-tween and further incubated for 1 h with the
corresponding secondary antibody conjugated with
horseradish peroxidase. Finally, membranes were washed
(3× 15 min) with TBS-tween and analyzed by chemilu-
miniscence (ECL Western Blotting Detection Reagents,
GE Healthcare, UK) using an image reader LAS-4000
(GE Healthcare, UK).
Analysis of ubiquitination
For ubiquitination assays, HEK293 cells were co-
transfected with pCMV-myc-PKM1 or pCMV-myc-
PKM2, 6xHis-tagged ubiquitin (WT, K48R or K63R)
plasmids and, when indicated, with pcDNA3-HA-malin
and pCMV-HA-laforin, or pCMV-Mdm2 plasmids,
using X-treme GENE transfection reagent, according to
the manufacturer’s instructions (Roche Diagnostics,
Barcelona, Spain). After 18 h of transfection, cells were
lysed in guanidinium hydrochloride to inhibit the ac-
tion of deubiquitinases and ubiquitinated proteins puri-
fied by metal affinity chromatography [12]. Bound
proteins and clarified extracts were analyzed by im-
munoblotting with the appropriated antibodies.
Determination of pyruvate kinase enzymatic activity
HEK293 cells transfected with the indicated plasmids were
resuspended in lysis buffer C [50 mMTrisHClpH 7.5,
1 mM EDTA, 150 mMNaCl, 1%NP-40, 1 mM DTT,
10 μM fructose 1,6 bisphosphateand complete protease
inhibitor mixture (Roche Diagnostics, Barcelona, Spain)].
Cells were lysed by repeated passage through 24G × 5/8″
needle and whole lysates were centrifuged at 10,000 × g
for 15 min. Clarified extracts were used to determine the
pyruvate kinase activity by standard methods (reaction
buffer: 40 mM K2HPO4 pH 7.6, 0.58 mM phosphoenol-
pyruvate, 0.11 mM NADH, 6.8 mM MgSO4, 1.5 mM
ADP, 10 units lactate dehydrogenase, 10 μM fructose 1,6
bisphosphate). The disappearance of NADH absorbance
was measured spectrophotometrically at 340 nm. One
unit of enzymatic activity is defined as the amount of
enzyme that is able to oxidize 1 μmol of NADH per 1 min
at 25 °C. Enzymatic activity was normalized by the total
amount of protein in the sample.
Immunofluorescence analysis
Human osteosarcoma U2OS cells transfected with the
indicated plasmids were grown on 12-well plates con-
taining coverslips. Cells were fixed with 4 % paraformal-
dehyde in phosphate-buffered saline (PBS) for 10 min.
Then, cells were permeabilized with 0.2 % Triton X-100
in PBS for 15 min, blocked 1 h with 10 % fetal bovine
serum, 5 % nonfat dried milk, 0.5 % BSA and 0.1 %
Triton X-100 in PBS, and incubated overnight at 4 °C in
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the same buffer containing anti-HA and anti-PKM2
antibodies. Samples were washed three timeswith PBS
and incubated with a 1/500 dilution of anti-mouse Texas
Red and anti-rabbit Alexa-Fluor 488 (Invitrogen, Madrid,
Spain). Then, cellswere washed three times with PBS and
mounted on slices using Aqua-Poly/Mount coverslipping
medium (Polysciences, Inc. Eppelheim, Germany). Images
were acquired with an uprightLeica DM RXA2microscope
using an PL APO 63× oil 1.4 N.A. immersion objective,
and the Leica IM50 software. At least 100 cells were
counted in each condition.
Statistical data analysis
Data are expressed as means with standard deviation.
Statistical significance of differences between the groups
was evaluated by a paired Student’s t-test with two-tailed
distribution. The significance has been considered at **
p < 0.01, as indicated.
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